Development and Clinical Application of Bispecific Antibody in the Treatment of Colorectal Cancer Publisher Pubmed



Balibegloo M^{1, 2} ; Rezaei N^{1, 3, 4}
Source: Expert Review of Clinical Immunology Published:2020

Abstract

Introduction: Treatment of colorectal cancer as one of the most commonly diagnosed and a frequent cause of cancer-related deaths is of great challenges in health-related issues. Areas covered: Immunotherapy is the fourth pillar of cancer treatment which provides more novel therapeutic options with expanding investigational potentials. One of the modalities in immunotherapy is the use of bispecific antibodies. Despite demonstrating many promising roles, it still needs more advanced studies to identify the actual pros and cons. In this review, the application of bispecific antibody in the treatment of colorectal cancer has been explained, based on preclinical and clinical studies. The literature search was conducted mainly through PubMed in June and September 2019. Expert opinion: Bispecific antibody is in its early stages in colorectal cancer treatment, requiring modern technologies in manufacturing, better biomarkers and more specific target antigens, more studies on individual genetic variations, and conducting later phase clinical trials and systematic reviews to achieve better survival benefits. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.